NEURONAX, the biopharmaceutical company specialized in neuronal regeneration, has been authorized to start its Phase I clinical trial by the Healthcare Authorities (French National Agency for Medicines and Health Products Safety (ANSM) for France and The Federal Agency for Medicines and Health Products (FAMHP) for Belgium). This first clinical trial in humans with the NX210 product is titled ” A Phase I Study to Investigate the Safety and Potential Activity of Single Intrathe